| Stereochemistry | RACEMIC |
| Molecular Formula | C15H23NO2 |
| Molecular Weight | 249.3486 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NCC(O)COC1=CC=CC=C1CC=C
InChI
InChIKey=PAZJSJFMUHDSTF-UHFFFAOYSA-N
InChI=1S/C15H23NO2/c1-4-7-13-8-5-6-9-15(13)18-11-14(17)10-16-12(2)3/h4-6,8-9,12,14,16-17H,1,7,10-11H2,2-3H3
CNS Activity
Originator
Approval Year
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
PubMed
Patents
Sample Use Guides
For treatment of hypertension and angina pectoris the initial dose of TENORMIN is 50 mg given as one tablet. If an optimal response is not achieved, the dosage should be increased to TENORMIN 100 mg given as one tablet a day. In patients with definite or suspected acute myocardial infarction, treatment with TENORMIN I.V. Injection should be initiated as soon as possible after the patient's arrival in the hospital and after eligibility is established. Such treatment should be initiated in a coronary care or similar unit immediately after the patient's hemodynamic condition has stabilized. Treatment should begin with the intravenous administration of 5 mg TENORMIN over 5 minutes followed by another 5 mg intravenous injection 10 minutes later.
Route of Administration:
Other
Binding of alprenolol to beta adrenergic receptors was measured using [3H]CGP 12177 as a radioligand in the ranges of 0.71-3.14 nM, and whole CHO cells, expressing beta1, beta2 and beta3 adrenergic receptors. Alprenolol inhibits binding of log Kd of -7.95, -9.3 and -6.86 for beta1, 2 and 3 respectively.
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
